Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Gastrointestinal 2Thoracic 1Sarcoma 1Head & Neck 1Gynecologic 1Genitourinary 1Dermatologic 1

Conditions

Breast Neoplasms 30Neoplasm Metastasis 10Carcinoma, Non-Small-Cell Lung 8Stomach Neoplasms 7Neoplasms 6Colorectal Neoplasms 6Adenocarcinoma 6Pancreatic Neoplasms 3Ovarian Neoplasms 3Endometrial Neoplasms 3Advanced Solid Tumor 3Triple Negative Breast Neoplasms 2Sarcoma 2Prostatic Neoplasms 2Melanoma 2HER2-positive Gastric Cancer 2Gastrointestinal Neoplasms 2Esophageal Neoplasms 2Carcinoma, Renal Cell 2Brain Neoplasms 2Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Urethral Neoplasms 1Unresectable Locally Recurrent Breast Cancer 1Thyroid Neoplasms 1Testicular Neoplasms 1Solid Cancer 1

Interventions

Bevacizumab 9Oxaliplatin 7Irinotecan 6Fluorouracil 6Nivolumab 5Leucovorin 5Cetuximab 5Capecitabine 5pembrolizumab 4Sunitinib 4IFL protocol 4Drug Therapy 4Cisplatin 4encorafenib 3Pemetrexed 3Gemcitabine 3Folfox protocol 35,10-methylenetetrahydrofolic acid 3trebananib 2trastuzumab deruxtecan 2amminedichloro(2-methylpyridine)platinum(II) 2Ocoxin 2N-(2-fluoro-4-((2-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)carbonylaminopyridin-4-yl)oxy)phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide 2Levoleucovorin 2IDRX-42 2CGX1321 2130-nm albumin-bound paclitaxel 2zanidatamab 1ulixertinib 1tivozanib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Gastrointestinal Neoplasms × trastuzumab deruxtecan × Clear all
NCT07124000 2026-06-01

DP-04

AstraZeneca

Recruiting
100 enrolled
DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Adenocarcinoma, Anus Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Liver Neoplasms, Melanoma, Mouth Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Salivary Gland Neoplasms, Sarcoma, Testicular Neoplasms, Thyroid Neoplasms, Urethral Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms, Endometrial Neoplasms, Gastrointestinal Stromal Tumors, Small Cell Lung Carcinoma

NCT03329690 2022-03-18

DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing Gastric Cancer [DESTINY-Gastric01]

Daiichi Sankyo

Phase 2 Completed
233 enrolled 26 charts 1 FDA
Gastrointestinal

Adenocarcinoma, Gastrointestinal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡